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The impact of disease prevalence on the predictive accuracy
of a diagnostic procedure can be calculated using the Bayes
theorum. In general, there is an inverse relation between
the prevalence of disease and the predictive accuracy of the
diagnostic test. However, at high prevalence of the disease,
the diagnostic accuracy of other means of diagnosis is so
great (that is, typical exercise-rest relation of angina in a
middle-aged man with several coronary risk factors) that
there may be little clinical value in performing the test.
Limitations of Bayesian approach. The limitations and
pitfalls of using the Bayesian approach to analyze clinical
decision-making have been thoroughly discussed in a de-
lightful essay by Alvan R. Feinstein entitled, "The Haze
of Bayes, The Aerial Palaces of Decision Analysis, and the
Computerized Ouija Board" (1). Feinstein summarized the
many disparities between the mathematical simplicity of the
Bayes formula and the realities of clinical reasoning and
clinical data. Among these are the fact that the formula
computes a numerical probability that is too vague and un-
certain for the demands of modem diagnostic precision. If
a patient has angina and it is the judgment of the clinician
that the diagnosis of coronary artery disease must be es-
tablished, coronary arteriography will be selected. This test
will reliably exclude the absence of coronary disease (so
that its probability is nearly 0) or confirm its existence (prob-
ability = 100%). One cannot insert the need to establish
the diagnosis in the Bayesian formula. In addition, Bayesian
clinical logic is aimed at diagnosis and it contains no pro-
vision for the situation where clinical reasoning terminates
with a trial of nitroglycerin, rather than additional diagnostic
tests.
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Assessment of cost-effectiveness ofdiagnostic tests. In
this issue of the Journal, Patterson et al. (2) have analyzed
the cost-effectiveness of different clinical approaches to di-
agnose coronary artery disease. Probability values of various
test modes were determined from data in their own insti-
tution and were based on specificity and sensitivity of the
tests in the diagnosis of coronary disease. These probability
values are undoubtedly specific for their institution and may
not apply to another. No matter, say the authors, one can
adjust the probability values depending on the experience
in one's institution. This, of course, poses a problem be-
cause most clinicians do not have ready availability of such
data.
Patterson and colleagues extend their Bayesian analysis
one step further to the assessment of cost-effectiveness. Therein
lies a whole set of new assumptions. Effectiveness is defined
as "either the number of patients with coronary disease
diagnosed or as the number of quality-adjusted life years
(Qaly) extended by therapy after the diagnosis of coronary
disease." This was calculated as the number of life years
extended by therapy over a 10 year follow-up period x the
adjusted quality of life, expressed as a fraction of full health
without symptoms. It was estimated that dQaly was in-
creased by 2 years in the patients correctly diagnosed as
having coronary disease. This analysis was based on the
assumption that patients correctly diagnosed were given the
benefit of surgical therapy, and this was a major factor in
the dQaly in this group (see their Fig. 6). The hypothesis
that the annual mortality rate of patients with stable ischemic
heart disease is less after coronary artery bypass surgery in
patients with mild stable angina has not been verified by
the data of the Coronary Artery Surgery Study (CASS) (3).
The CASS study is probably applicable to the patient pop-
ulation study of Patterson et al. since they limited their
analysis to patients with stable angina who could exercise
to at least 85% of their maximal anticipated heart rate and,
therefore, are likely to have good left ventricular function.
There are other assumptions in this paper that could be
questioned, but space does not permit a full analysis.
Applications of the study. Why should one be critical
of an honest and thoughtful attempt to assess the difficult
problem of cost-effectiveness of various approaches in the
diagnosis of coronary artery disease? One of the stated ob-
jectives of this analysis is to present an approach to the
problem because of the impact of coronary disease on the
total health care budget and rising health care costs. It is
evident that there will be a need for physicians to become
increasingly cost-conscious regarding the diagnosis and
treatment of this disease. Experienced cardiologists will have
no difficulty in recognizing which diagnostic approaches to
select for the individual patient, but will the health care
administrator who may use published data on cost-effec-
tiveness and who decides whether reimbursement for ser-
vices is appropriate be able to recognize the many uncer-
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tainties and variables that go into decision-making? For this
reason, one must be able to recognize the limitations of
studies that purport to analyze cost-effective approaches to
the delivery of health care.
Undoubtedly, controversy will continue regarding the
utility of the Bayesian approach to clinical decision-making.
Feinstein (1) stated, "I know of no clinical setting or in-
stitution in which Bayesian diagnostic methods are being
regularly used for practical diagnostic purposes in a routine
or even specialized manner. 1 know of no specific, con-
structive, practical diagnostic decision involving real-world
patient" data and doctors, in which Bayesian methods have
made a prominent contribution that could not have been
achieved just as easily without Bayes' formula."
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